OncoMatch/Clinical Trials/NCT05190705
Loncastuximab Tesirine in WM
Is NCT05190705 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Loncastuximab Tesirine and Dexamethasone for waldenstrom macroglobulinemia.
Treatment: Loncastuximab Tesirine · Dexamethasone — This study is being done to examine the safety and effectiveness of loncastuximab tesirine as a possible treatment for participants with Waldenström Macroglobulinemia (WM). The name of the study drug involved in this study is: * Loncastuximab tesirine
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anti-CD20 monoclonal antibody-containing regimen
At least 2 prior lines of treatment, including an anti-CD20 monoclonal antibody-containing regimen
Must have received: BTK inhibitor
At least 2 prior lines of treatment, including ... a BTK inhibitor
Cannot have received: CD19 targeted therapy
Prior treatment with CD19 targeted therapy.
Lab requirements
Blood counts
Absolute neutrophil count ≥1000/ uL (no growth factors <14 days prior to C1D1); Platelets ≥50,000/ uL (no platelet transfusions <14 days prior to C1D1); Hemoglobin ≥ 7 g/dL (no RBC transfusions <14 days prior to C1D1)
Kidney function
Creatinine clearance ≥ 30 ml/min using Cockcroft/Gault formula
Liver function
Total bilirubin ≤ 1.5 X ULN, or ≤3 x ULN with documented liver metastases and/or Gilbert's Disease; AST(SGOT)/ALT(SGPT) ≤2.5 × institutional upper limit of normal, or ≤5 X ULN with documented liver metastases
Participants must have normal organ and marrow function as defined below: * Absolute neutrophil count ≥1000/ uL. Growth factors are not permitted <14 days prior to C1D1. * Platelets ≥50,000/ uL. Platelet transfusions are not permitted <14 days prior to C1D1. * Hemoglobin ≥ 7 g/dL. RBC transfusions are not permitted <14 days prior to C1D1. * Total bilirubin ≤ 1.5 X ULN, or ≤3 x ULN with documented liver metastases and/or Gilbert's Disease * AST(SGOT)/ALT(SGPT) ≤2.5 × institutional upper limit of normal, or ≤5 X ULN with documented liver metastases * Creatinine clearance ≥ 30 ml/min using Cockcroft/Gault formula
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Dana Farber Cancer Institute · Boston, Massachusetts
- Beth Israel Deaconess Medical Center · Boston, Massachusetts
- Mayo Clinic · Rochester, Minnesota
- Fred Hutch · Seattle, Washington
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify